Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients

Polish Journal of Pathology

Volumn 62, Issue 4, 2011, Pages 218-228

  Kukla, Michał ^a   Berdowska, Agnieszka ^b   Gabriel, Andrzej ^a   Sawczyn, Tomasz ^a   Mazur, Włodzimierz ^a   Sobala Szczygieł, Barbara ^a   Grzonka, Dariusz ^a   Zajecki, Wojciech ^a   Tomaszek, Krzysztof ^a   Bułdak, Rafał J ^a   Zwirska Korczala, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Adipokines; Adiponectin; Angiogenesis; Chemerin; Chronic hepatitis C; Fibrosis; Leptin; Liver; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN, HUMAN; CHEMERIN, HUMAN; CHEMOKINE; CYTOKINE; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD; FEMALE; HEPATITIS C; HUMAN; LIVER; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; SEX DIFFERENCE; VASCULARIZATION; VIROLOGY;

ADIPOKINES; ADIPONECTIN; ADULT; CHEMOKINES; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LEPTIN; LIVER; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; SERPINS; SEX FACTORS; YOUNG ADULT;

EID: 84855799544     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Chaparro M, Sanz-Cameno P, Trapero-Marugan M, et al. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 2007; 6: 208-213.
2. Medina J, Arroyo AG, Sánchez-Madrid F,Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195.
3. Kukla M, Gabriel A,Waluga M, et al. Angiogenesis in chronic viral hepatitis. Gastroenterol Pol 2009; 16: 304-309.
4. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6: 170-173.
5. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
6. Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
7. Shimizu I. Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord 2001; 1: 227-240.
8. Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007; 170: 942-953.
9. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969.
10. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101.
11. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348.
12. Anagnostoulis S, Karayiannakis AJ, Lambropoulou M, et al.Human leptin induces angiogenesis in vivo. Cytokine 2008; 42: 353-357.
13. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365.
14. Kaur J, Adya R, Tan BK, et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010; 391: 1762-1768.
15. Robertson SA, Rae CJ, Graham A. Induction of angiogenesis bymurine resistin: putative role of PI3-kinase and NO-dependent pathways. Regul Pept 2009; 152: 41-47.
16. Bråkenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspasemediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101: 2476-2481.
17. Fu BD, Yamawaki H, Okada M, Hara Y. Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J Vet Med Sci 2009; 71: 1201-1207.
18. Mazzanti R, Messerini L, Monsacchi L, et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997; 25: 229-234.
19. Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701.
20. Gabriel A, Kukla M, Wilk M, et al. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathol Res Pract 2009; 205: 758-764.
21. Kukla M, Gabriel A, Sabat D, et al. Association between liver steatosis and angiogenesis in chronic hepatitis C. Pol J Pathol 2010; 61: 154-160.
22. Strauss LC, Rowley SD, La Russa VF, et al. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol 1986; 14: 878-886.
23. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti- CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-3415.
24. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112-114.
25. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
26. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on themethodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-2484.
27. McCuskey RS, Reilly FD. Hepatic microvasculature: dynamic structure and its regulation. Semin Liver Dis 1993; 13: 1-12.
28. Camenisch G, Pisabarro MT, Sherman D, et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta3 and induces blood vessel formation in vivo. J Biol Chem 2002; 277: 17281-17290.
29. Huebert RC, Vasdev MM, Shergill U, et al. Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology 2010; 52: 238-248.
30. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640.
31. Suganami E, Takagi H, Ohashi H, et al. Leptin stimulates ischemia- induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004; 53: 2443-2448.
32. Cao R, Brakenhielm E, Wahlestedt C, et al. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 2001; 98: 6390-6395.
33. Grosfeld A, Zilberfarb V, Turban S, et al. Hypoxia increases leptin expression in human PAZ6 adipose cells. Diabetologia 2002; 45: 527-530.
34. Zwirska-Korczala K, Kukla M, Ziolkowski A, et al. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp Clin Hep 2005; 1: OR60-65.
35. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004; 11: 91-96.
36. Shimizu H, Kakizaki S, Tsuchiya T, et al. An increase of circulating leptin in patients with liver cirrhosis. Int J Obes Relat Metab Disord 1998; 22: 1234-1248.
37. Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not with histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43: 235-242.
38. Handy JA, Saxena NK, Fu P, et al. Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem2010; 110: 1195-1207.
39. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
40. Kukla M, Zwirska-Korczala K, Gabriel A, et al. Visfatin serum levels in chronic hepatitis C patients. J Viral Hepat 2010; 17: 254-260.
41. Kukla M, Zwirska-Korczala K, Gabriel A, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J ViralHepat 2010; 17: 661-667.
42. Bozaoglu K, Curran JE, Stocker CJ, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab 2010; 95: 2476-2485.
43. Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. J Endocrinol 2006; 189: 691-699.
44. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
45. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovas Res 2006; 70: 146-157.
46. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340.
47. Bertolani C, Sancho-Bru P, Failli P, et al. Resistin as an intrahepatic cytokine. Overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006; 169: 2042-2053.
48. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-1136.
49. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-10615.
50. McIlroy M, O'Rourke M, McKeown SR, et al. Pericytes influence endothelial cell growth characteristics: role of plasminogen activator inhibitor type 1 (PAI-1). Cardiovasc Res 2006; 69: 207-217.
51. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
52. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenterology 2003; 125: 1695-1704.
53. Kukla M, Mazur W, Buldak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokin - visfatin, chemerin and vaspin - in chronic hepatitis. MalMed 2011: 17: 1397-1410.
54. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
55. Kukla M, Sarczyn T, Zwirska-Korczala K, Jarosz M. Pathomechanism of insulin resistance in chronic hepatitis C. Przegl Gastroenterol 2011; 6: 284-289.
56. Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune response in chronic hepatitis C virus infection. Hepatology 2008; 48: 374-384.